| ¿µ¹® | autonomic nervous system | ÇÑ±Û | ÀÚÀ²½Å°æ°è |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ÀÇÁö¿Í °ü°è¾øÀÌ, ħÀ» È긮°Å³ª ¼Òȿ µî°ú °°Àº ½º½º·Î Á¶Á¤ÀÌ µÇ¾î ¿òÁ÷ÀÌ´Â ½Å°æ°èÀÌ¸ç ¿©±â¿¡´Â ´ÙÀ½°ú °°Àº µÎ °¡Áö°¡ ÀÖ´Ù. 1.±³°¨½Å°æ°è(sympathetic nervous system)-»ç¶÷ÀÌ À§Çè»óÅ¿¡ À̸£·¶À» °æ¿ì¿¡ ÈïºÐÀÌ µÇ´Â ÀÚÀ²½Å°æ°è. Áï ½É¹Ú¼öÀÇ Áõ°¡, ¼Òȱ⠿ÀÇ °¨¼Ò µîÀÇ ÀÏÀÌ À̰÷À» ÅëÇØ¼ ÀϾÙ. ±³°¨½Å°æÀÌ ÈïºÐµÇ¸é ±³°¨½Å°æÀÇ ¸»´Ü¿¡¼ epinephrine, norepinephrine µîÀÇ ¹°ÁúÀÌ ºÐºñµÇ°í À̰͵鿡 ÀÇÇØ¼ ¸»ÃÊÀå±â°¡ º¯È¸¦ ÀÏÀ¸Å²´Ù. ÇÏÁö¸¸ Àå±â¿¡ µû¶ó¼ epinephrineÀ̳ª norepinephrineÀÇ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ¾î¼ ¿©·¯ °¡Áö ´Ù¸¥ Àå±âÀÇ ¹ÝÀÀÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¼ö¿ëü´Â ´ÙÀ½°ú °°´Ù. -¾ËÆÄ¼ö¿ëü(alpha-receptor): ¸»ÃÊÇ÷°üÀÇ ¼öÃà, ±â°üÁöÀÇ ¼öÃà, µ¿°øÀÇ ±ÙÀ°ÀÇ ¼öÃà -º£Å¸1¼ö¿ëü(beta 1-receptor): ½ÉÀå¿¡ Á¸ÀçÇÏ´Â ¼ö¿ëü, ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. -º£Å¸2¼ö¿ëü(beta 2-receptor): Ç÷°üÀÇ ÀÌ¿Ï, ±â°üÁöÀÇ ÀÌ¿Ï, Áï °¢ Àå±âµéÀº ±× Àå±â°¡ °¡Áö°í ÀÖ´Â ±³°¨½Å°æÀÇ ¼ö¿ëü¿¡ µû¶ó ±³°¨½Å°æÀÇ ÈïºÐ(±³°¨½Å°æ ¸»´Ü¿¡¼ÀÇ epinephrineÀÇ ºÐºñ)¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ´Þ¶óÁø´Ù(¿¹-±³°¨½Å°æÀÌ ÈïºÐ½Ã¿¡ beta 1-¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Â ½ÉÀåÀº »¡¸® ¶Ù°Ô µÈ´Ù. ±³°¨½Å°æ ÈïºÐ½Ã¿¡ µ¿°øÀÇ ±ÙÀ°ÀÌ ¼öÃàÇØ¼ µ¿°øÀÇ Å©±â°¡ Ä¿Áø´Ù) 2.ºÎ±³°¨½Å°æ°è(parasympathetic nervous system)-±³°¨½Å°æ°ú ¹Ý´ë·Î ÀÛ¿ëÇÑ´Ù. Áï »ç¶÷ÀÌ Á¹¸®°Å³ª ½¯ °æ¿ì¿¡ ÈïºÐÇÑ´Ù. ºÎ±³°¨½Å°æÀÌ ÈïºÐÇÒ ¶§¿¡´Â ½Å°æÀÇ ¸»´Ü¿¡¼ ¾Æ¼¼Ä¥Äݸ°ÀÇ ºÐºñ°¡ ÀϾ°í À̰ÍÀ¸·Î ÀÎÇØ¼ °¢ Àå±âÀÇ º¯È°¡ ÀϾÙ. |
||
| ¿µ¹® | TNM staging system | ÇÑ±Û | Á¾¾çº´±âºÐ·ù°èÅë |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤ÇÏ´Â ÇÑ ¹æ¹ý. T´Â Tumor(Á¾¾ç)¸¦ ¶æÇÏ¸ç ¿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀÇ Ä§À±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î ħÀ±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù. NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç ħ¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù. MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇÏ¸ç ¿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù. ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀÎ º´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | central nervous system(CNS) | ÇÑ±Û | ÁßÃ߽Űæ°è |
|---|---|---|---|
| ¼³¸í | ½Å°æ°è´Â ÁßÃ߽Űæ°è¿Í ¸»ÃʽŰæ°è·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ´Ù. ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö·Î ±¸¼ºµÇ¾î ÀÖ´Â ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. ¸»ÃʽŰæ°è¶õ ÀÌ ÀÌ¿ÜÀÇ ¸ðµç ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. |
||
| immune response | <immunology> Alteration in the reactivity of an organisms immune system in response to an antigen, in vertebrates, this may involve antibody production, induction of cell-mediated immunity, complement activation or development of immunological tolerance. (18 Nov 1997) |
|---|---|
| immune-response gene | <molecular biology> Any of several genes of the major histocompatibility complex that control the immune response of lymphocytes to specific antigens. (09 Oct 1997) |
| immune response genes | Gene's in the HLA-D region of the histocompatibility complex of human chromosome 6 which control the immune response to specific antigens. (05 Mar 2000) |
| immune sera | Serum that contains antibodies. It is obtained from an animal that has been immunised either by antigen injection or infection with microorganisms containing the antigen. (12 Dec 1998) |
| immune serum | Blood serum containing antibodies. (14 Nov 1997) |
| immune serum globulin | A sterile solution of globulin's that contains many antibodies normally present in adult human blood; a passive immunizing agent frequently used for prophylaxis against hepatitis A. (05 Mar 2000) |
| immune suppression | Suppression of the immune response by some compound or agent. (05 Mar 2000) |
| immune surveillance | <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells. (18 Nov 1997) |
| immune thrombocytopenia | Thrombocytopenia associated with antiplatelet antibodies. See: isoimmune neonatal thrombocytopenia, autoimmune neonatal thrombocytopenia. (05 Mar 2000) |
| immune thrombocytopenic purpura | <haematology> A low number of platelets in the blood, which is common in people with HIV, but often resolves as immune deficiency worsens. HIV-related ITP usually does not have serious consequences. Its cause has not been definitely determined. Treatment with AZT frequently alleviates the condition. (09 Oct 1997) |
| immune tolerance | The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. (12 Dec 1998) |
| tetanus immune globulin | <protein> A protein antibody to tetanus toxin, given as passive immunity for those lacking any prior tetanus vaccination. (27 Sep 1997) |
| zoster immune globulin | A globulin fraction of pooled plasma from individuals who have recovered from herpes zoster; used prophylactically and therapeutically for varicella. (05 Mar 2000) |
| acoustic nerve diseases | Diseases of the eighth cranial nerve. These include vestibular neuronitis, cochlear neuritis and acoustic neuroma. (12 Dec 1998) |
| adaptation diseases | Disease's falling theoretically into Selye's concept of the general-adaptation syndrome. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|